Can I read PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1) on EtoBox?

PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1) by A Shim; D Trone; M Reynolds; D Odom; B Sherif; S Stopatschinskaja is a Economics, Econometrics and Finance article available to read on EtoBox.

What is PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1) about?

WHOQOL-BREF),nurse-perceived patient adverse events, in addition to questions about demographic traits, intent to quit, and job satisfaction. Results: The suggested theoretical model is an integration of the results of empirical research related to pediatric nurses' burnout, quality of life, perceived adverse events, job satisfaction, social support, Compassion Satisfaction -Compassion Fatigue model, and the empowerment model. Conclusions: The proposed model might be suitable in directing future studies discovering scientific gaps about burnout, quality of life, job satisfaction, social support, and perceived adverse events among pediatric nurses during and after the COVID-19 pandemic. Also, this model will provide an inclusive theoretical framework for future studies examining nurses' burnout.

Who reads PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)?

Author

A Shim; D Trone; M Reynolds; D Odom; B Sherif; S Stopatschinskaja

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Economics, Econometrics and Finance (Social Sciences)